Health systems across the country are making it easier for primary care clinicians to order genetic tests for patients who ...

In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor-informed, ...

This collaboration will streamline the ordering and delivery of molecular tests, enabling healthcare providers to electronically order and track Prolaris and MyRisk tests, with results delivered ...

The company, founded by 25-year-old Kian Sadeghi, announced a $14 million Series A, bringing its total funding to about $32 million.

In two new papers, researchers from The Jackson Laboratory (JAX) report the successful use of two approaches—gene therapy and ...

PRNewswire London [UK] Munich [Germany] New Delhi [India] January 22 Datar Cancer Genetics DCG today announced the launch of ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...

Researchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics ...

Matthew Moll, MD, MPH, and Michael H. Cho, MD, MPH, from the Department of Medicine at Brigham and Women's Hospital are ...

Seattle doctors developed a blood test that determines the parental origin of the RB1 mutation in retinoblastoma.

Datar Cancer Genetics (DCG) has launched a revolutionary video-reporting service for in-vitro chemosensitivity testing, ...